{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-058659","form_type":"8-K/A","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.856628+00:00","generated_at":"2026-06-07T09:51:49.298912+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant files pro forma financials for $7.1B Telavant sale to Roche; gain of $5.3B","bullets":["Roivant sold its 75% stake in Telavant to Roche for ~$7.1B cash plus $150M milestone for Phase 3 trial initiation.","Pro forma cash and cash equivalents at Sep 30, 2023: $6.6B, up from $1.4B historical.","Pro forma net income attributable to Roivant for FY Mar 2023: $4.3B vs historical net loss of $1.1B.","Pro forma net loss for H1 Sep 2023: $552M vs historical loss of $596M; reduction from eliminated Telavant R&D.","Transaction accounted for as sale of nonfinancial assets; $5.3B gain recognized."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-058659","json":"https://secwatch.observer/filing/0001140361-23-058659.json","markdown":"https://secwatch.observer/filing/0001140361-23-058659.md","text":"https://secwatch.observer/filing/0001140361-23-058659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123058659/0001140361-23-058659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123058659/ef20017039_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:51:49.298912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}